| Identification | More | [Name]
Folic acid | [CAS]
59-30-3 | [Synonyms]
ACIDUM FOLICUM
CYTOFOL
FOLACIN
FOLIC ACID
FOLIC ACID HYDRATE
FOLSAN
FOLSAURE
INCAFOLIC
l-pteroylglutamic acid
n-4-[(2-amido-4-oxo-1,4-dihydro-6-terene)methylamino]benzoyl-l-glutamic acid
N-[4-[[(2-AMINO-4-HYDROXY-6-PTERIDYL)METHYL]AMINO]BENZOYL]GLUTAMIC ACID
PGA
PTEGLU
PTEROYGLUTAMIC ACID
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
Vitamin B11
VITAMIN BC
VITAMIN M | [EINECS(EC#)]
200-419-0 | [Molecular Formula]
C19H19N7O6 | [MDL Number]
MFCD00079305 | [Molecular Weight]
441.4 | [MOL File]
59-30-3.mol |
| Chemical Properties | Back Directory | [Appearance]
orange to yellow crystalline powder | [Melting point ]
250 °C
| [alpha ]
20 º (c=1, 0.1N NaOH) | [Boiling point ]
552.35°C (rough estimate) | [density ]
1.4704 (rough estimate) | [refractive index ]
1.6800 (estimate) | [storage temp. ]
2-8°C
| [solubility ]
boiling water: soluble1% | [form ]
Crystalline Powder | [pka]
pKa 2.5 (Uncertain) | [color ]
Yellow to orange | [Odor]
Odorless | [PH Range]
4 | [Stability:]
Stable. Incompatible with heavy metal ions, strong oxidizing agents, strong reducing agents. Solutions may be light and heat sensitive. | [Water Solubility ]
1.6 mg/L (25 ºC) | [Merck ]
4221 | [BRN ]
100781 | [BCS Class]
3 | [InChIKey]
OVBPIULPVIDEAO-LBPRGKRZSA-N | [LogP]
-0.990 (est) | [Uses]
folic acid(59-30-3) is generally used as an emollient. In vitro and in vivo skin studies now indicate its capacity to aid in DnA synthesis and repair, promote cellular turnover, reduce wrinkles, and promote skin firmness. There is some indication that folic acid may also protect DnA from uV-induced damage. Folic acid is a member of the vitamin B complex and is naturally occurring in leafy greens.
| [CAS DataBase Reference]
59-30-3(CAS DataBase Reference) | [NIST Chemistry Reference]
Folic acid(59-30-3) | [EPA Substance Registry System]
59-30-3(EPA Substance) |
| Safety Data | Back Directory | [Risk Statements ]
R33:Danger of cumulative effects.
R62:Possible risk of impaired fertility.
R68:Possible risk of irreversible effects. | [Safety Statements ]
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
1
| [RTECS ]
LP5425000
| [F ]
8 | [TSCA ]
Yes | [HS Code ]
29362910 | [Safety Profile]
Poison by
intraperitoneal and intravenous routes.
Experimental teratogenic effects. Mutation
data reported. When heated to
decomposition it emits toxic fumes of NOx. | [Hazardous Substances Data]
59-30-3(Hazardous Substances Data) | [Toxicity]
A water soluble vitamin
required in the diet of mammals. Sulfonamide drugs are selectively
toxic to bacteria because they inhibit the incorporation
of p-aminobenzoic acid into folic acid, a biosynthetic process
in bacteria. Folic acid deficiency adversely affects prenatal
development in humans. Dietary supplementation with folic
acid dramatically reduces the incidence of neural tube defects
in humans. Folic acid deficiency may also contribute to the causes of megaloblastic macrocytic anemia and a consequence
of this is that this disease can be induced, as a side effect,
when methotrexate, a folic acid antagonist, is used in cancer
chemotherapy |
| Hazard Information | Back Directory | [General Description]
Odorless orange-yellow needles or platelets. Darkens and chars from approximately 482°F. | [Reactivity Profile]
Acid solutions of FOLIC ACID(59-30-3) are sensitive to heat, but towards neutrality, stability progressively increases. Solutions are inactivated by ultraviolet light and alkaline solutions are sensitive to oxidation. FOLIC ACID(59-30-3) is also inactivated by light. This chemical is incompatible with oxidizing agents, reducing agents and heavy metal ions. | [Air & Water Reactions]
Insoluble in water. Aqueous solutions have pHs of 4.0-4.8. | [Fire Hazard]
Flash point data for this chemical are not available; however, FOLIC ACID is probably combustible. | [Chemical Properties]
orange to yellow crystalline powder | [Physical properties]
The folates include a large number of chemically related species, each differing
with respect to the various substituents possible at three sites on the pteroylglutamic
acid basic structure. More than 170 different folates are theoretically possible. Not
all of these occur in nature; but it has been estimated that as many as 100 different
forms are found in animals. The folates from most natural sources usually have a
single carbon unit at N-5 and/or N-10; these forms participate in the metabolism of
the single-carbon pool.
Folic acid (pteroylmonoglutamic acid) is an orange-yellow crystalline substance
that is soluble in water but insoluble in ethanol or less polar organic solvents. It is
unstable to light, to acidic or alkaline conditions, to reducing agents, and, except in
dry form, to heat. It is reduced in vivo enzymatically (or in vitro with a reductant
such as dithionite) first to 7,8-dihydrofolic acid (FH2) and then to FH4; both of these
compounds are unstable in aerobic environments and must be protected by the pres ence of an antioxidant (e.g., ascorbic acid, 2-mer
Two derivatives of folic acid, each having an amino group in the place of the
hydroxyl at C-4, are folate antagonists of biomedical use: aminopterin (4-aminofolic
acid) and methotrexate (4-amino-N10-methylfolic acid). Aminopterin is used as a
rodenticide; methotrexate is an antineoplastic agent. | [Originator]
Folvite, Lederle, US ,1946 | [Occurrence]
Synthetic | [Definition]
ChEBI: An N-acyl-amino acid that is a form of the water-soluble vitamin B9. Its biologically active forms (tetrahydrofolate and others) are essential for nucleotide biosynthesis and homocysteine remethylation. | [Manufacturing Process]
The following description is taken from US Patent 2,956,057.
100 grams of 1,3,3-trichloroacetone are heated on a boiling water bath and
95 grams of bromine are added thereto in drops while being stirred and the
stirring is continued for about 1 hour. The resulting reaction solution is
distilled under reduced pressure. 115 grams of 1-bromo-1,3,3-
trichloroacetone are obtained having a boiling point of 85° to 95°C/17 mm
(Hg).
For the preparation of the hydrate, 100 grams of water are added to 100
grams of 1bromo-1,3,3-trichloroacetone, which is agitated and cooled. A white
scaly crystal of hydrate of 1-bromo-1,3,3-trichloroacetone is obtained (100
grams), having a melting point of 52° to 53°C.
8.9 grams of 2,4,5-triamino-6-hydroxypyrimidine hydrochloride and 8 grams
of p-aminobenzoylglutamic acid are dissolved in 400 cc warm water, which is
cooled at 35° to 27°C and adjusted to pH 4 by using 20% caustic soda
solution. To this solution was simultaneously added dropwise a solution
obtained by dissolving 13.4 grams of 1-bromo-1,3,3-trichloroacetone hydrate
in 90 cc of 50% methanol and 24 grams of 35% aqueous sodium bisulfite
solution over a period of approximately 2 hours. During this period, in order
to maintain the pH value of the reaction solution at 4 to 5, 20% caustic soda
solution is added from time to time. The precipitate, formed by stirring for 5
hours after dropping was finished, is filtered, and the filtrated precipitate is
refined; 5.6 grams of pure pteroylglutamic acid is obtained. | [Therapeutic Function]
Treatment of B vitamin (folacin) deficiency | [Biochem/physiol Actions]
A nutritional delivery form of folate. Folic acid and its derivatives are essential mediators of one-carbon metabolism within cells. | [Clinical Use]
Folate-deficient megaloblastic anaemia
Supplement in HD patients | [Veterinary Drugs and Treatments]
Folic acid(59-30-3) is used to treat folic acid deficiency in dogs, cats, and
horses (theoretically in other animal species as well) often due to
small intestinal disease. Cats with exocrine pancreatic insufficiency
appear to be most at risk for folate and cobalamin deficiencies secondary
to malabsorption of folic acid in the diet. Dogs with exocrine
pancreatic insufficiency often are noted to have increased folate levels
secondary to overgrowths of folate-synthesizing bacteria in the
proximal small intestine. Chronic administration of dihydrofolate
reductase inhibiting drugs such as pyrimethamine, ormetoprim or
trimethoprim can potentially lead to reduced activated folic acid
(tetrahydrofolic acid); folic acid supplementation is sometimes prescribed
in an attempt to alleviate this situation.
| [Drug interactions]
Potentially hazardous interactions with other drugs
Antiepileptics: reduces phenytoin, primidone and
phenobarbital levels.
Cytotoxics: avoid with raltitrexed. | [Metabolism]
Folic acid given therapeutically enters the portal
circulation largely unchanged, since it is a poor substrate
for reduction by dihydrofolate reductase. It is converted
to the metabolically active form 5-methyltetrahydrofolate
in the plasma and liver. Folate undergoes enterohepatic
circulation. Folate metabolites are eliminated in the urine
and folate in excess of body requirements is excreted
unchanged in the urine. | [Purification Methods]
If paper chromatography indicates impurities, then recrystallise it from hot H2O or from dilute acid [Walker et al. J Am Chem Soc 70 19 1948]. Impurities may be removed by repeated extraction with n-BuOH of a neutral aqueous solution of folic acid (by suspending in H2O and adding N NaOH dropwise till the solid dissolves, then adjusting the pH to ~7.0-7.5) followed by precipitation with acid, filtration, or better collected by centrifugation and recrystallised form hot H2O. [Blakley Biochem J 65 331 1975, Kalifa et al. Helv Chim Acta 6 1 2739 1978.] Chromatography on cellulose followed by filtration through charcoal has also been used to obtain pure acid. [Sakami & Knowles Science 129 274 1959.] UV: max 247 and 296nm ( 12,800 and 18,700) in H2O pH 1.0; 282 and 346nm ( 27.600 and 7,200) in H2O pH 7.0; 256, 284 and 366nm ( 24600, 24,500 and 86,00) in H2O pH 13 [Rabinowitz in The Enzymes (Boyer et al. Eds), 2 185 1960]. [Beilstein 26 III/IV 3944.] |
| Questions And Answer | Back Directory | [Description]
Folic acid (folate,59-30-3) is a kind of B-vitamin which is mainly present in the liver and kidney. It has various kinds of pharmacological and physiological effects. It is involved in amino acid metabolism, purine and pyrimidine synthesis, and is also essential for hematopoiesis and red blood cell generation. In women pregnancy, folate can effectively prevent neural tube defects in the baby. It plays important role in fertility through contributing to spermatogenesis. It can also reduce the incidence of heart disease, stroke and cancer.
Folate deficiency may lead to various kinds of diseases including glossitis, diarrhea, depression, confusion, anemia, and fetal neural tube defectsand brain defects (during pregnancy). Other symptoms may include fatigue, gray hair, mouth sores, poor growth, and swollen tongue.
|
|
|